Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 176 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2015', provides an overview of the Keratoconjunctivitis sicca (Dry Eye)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Keratoconjunctivitis sicca (Dry Eye) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Keratoconjunctivitis sicca (Dry Eye) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Keratoconjunctivitis sicca (Dry Eye) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Keratoconjunctivitis sicca (Dry Eye) Overview 8
Therapeutics Development 9
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview 9
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis 10
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies 11
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies 19
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 22
Allergan, Inc. 22
Celsus Therapeutics Plc 23
Circadian Technologies Limited 24
Digna Biotech, S.L. 25
Dompe Farmaceutici S.p.A. 26
Dong-A Socio Group 27
Eleven Biotherapeutics Inc. 28
EyeGate Pharmaceuticals, Inc. 29
HanAll Biopharma Co., Ltd. 30
Herantis Pharma plc. 31
Huons Co., Ltd. 32
InSite Vision Incorporated 33
Kainos Medicine, Inc. 34
Kala Pharmaceuticals, Inc. 35
Kissei Pharmaceutical Co., Ltd. 36
Laboratorios Sophia S.A. de C.V. 37
Lipicard Technologies Limited 38
LTT Bio-Pharma Co., Ltd. 39
Merck & Co., Inc. 40
Mimetogen Pharmaceuticals Inc. 41
Neuroptis Biotech 42
NovaBay Pharmaceuticals, Inc. 43
Novaliq GmbH 44
Ocular Therapeutix, Inc. 45
OncoNOx ApS 46
Otsuka Holdings Co., Ltd. 47
Parion Sciences, Inc. 48
R-Tech Ueno, Ltd. 49
RegeneRx Biopharmaceuticals, Inc. 50
Resolvyx Pharmaceuticals, Inc 51
Santen Pharmaceutical Co., Ltd. 52
Scynexis, Inc. 53
Seikagaku Corporation 54
Shire Plc 55
SIFI S.p.A 56
Winston Pharmaceuticals, Inc. 57
Xigen SA 58
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Target 60
Assessment by Mechanism of Action 63
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
cyclosporine - Drug Profile 69
cyclosporine - Drug Profile 70
cyclosporine - Drug Profile 73
cyclosporine - Drug Profile 74
cyclosporine Nanoemulsion - Drug Profile 75
dexamethasone acetate - Drug Profile 76
dexamethasone acetate SR - Drug Profile 78
diclofenac sodium - Drug Profile 79
diquafosol tetrasodium - Drug Profile 80
disitertide - Drug Profile 82
EBI-005 - Drug Profile 85
HL-036 - Drug Profile 87
ISV-101 - Drug Profile 88
KBP-7306 - Drug Profile 89
KeraKlear - Drug Profile 90
KL-7016 - Drug Profile 91
KM-401 - Drug Profile 92
Lacripep - Drug Profile 93
lifitegrast - Drug Profile 94
loteprednol etabonate - Drug Profile 97
MIMD-3 - Drug Profile 99
NOP-3 - Drug Profile 100
NOP-5 - Drug Profile 101
NVC-638 - Drug Profile 102
NVC-704 - Drug Profile 103
NVC-727 - Drug Profile 104
OPX-1 - Drug Profile 105
OTX-101 - Drug Profile 106
OX-1001 - Drug Profile 107
ozagrel - Drug Profile 108
P-1037 - Drug Profile 109
P-17 - Drug Profile 110
P-321 - Drug Profile 112
plastoquinone decyl triphenylphosphonium bromide - Drug Profile 113
PRO-148 - Drug Profile 115
rebamipide - Drug Profile 117
recoflavone - Drug Profile 119
Recombinant Human Nerve Growth Factor - Drug Profile 121
RGN-259 - Drug Profile 122
RU-101 - Drug Profile 124
ruclosporin - Drug Profile 125
RX-10005 - Drug Profile 126
RX-20001 - Drug Profile 127
SF-104 - Drug Profile 128
SI-614 - Drug Profile 129
Urocanic Acid - Drug Profile 130
VGX-100 - Drug Profile 132
XG-104 - Drug Profile 134
zucapsaicin - Drug Profile 135
Keratoconjunctivitis sicca (Dry Eye) - Recent Pipeline Updates 137
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 159
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 163
Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 164
Featured News & Press Releases 164
Appendix 171
Methodology 171
Coverage 171
Secondary Research 171
Primary Research 171
Expert Panel Validation 171
Contact Us 171
Disclaimer 172

List of Tables
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2015 13
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Comparative Analysis by Late Stage Development, H1 2015 19
Comparative Analysis by Clinical Stage Development, H1 2015 20
Comparative Analysis by Early Stage Development, H1 2015 21
Comparative Analysis by Unknown Stage Development, H1 2015 22
Products under Development by Companies, H1 2015 23
Products under Development by Companies, H1 2015 (Contd..1) 24
Products under Development by Companies, H1 2015 (Contd..2) 25
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan, Inc., H1 2015 26
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Celsus Therapeutics Plc, H1 2015 27
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Circadian Technologies Limited, H1 2015 28
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H1 2015 29
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H1 2015 30
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dong-A Socio Group, H1 2015 31
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Eleven Biotherapeutics Inc., H1 2015 32
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2015 33
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 34
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma plc., H1 2015 35
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H1 2015 36
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H1 2015 37
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kainos Medicine, Inc., H1 2015 38
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H1 2015 39
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 40
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2015 41
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H1 2015 42
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2015 43
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H1 2015 44
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H1 2015 45
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H1 2015 46
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 47
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H1 2015 48
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H1 2015 49
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H1 2015 50
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 51
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H1 2015 52
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by R-Tech Ueno, Ltd., H1 2015 53
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2015 54
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Resolvyx Pharmaceuticals, Inc, H1 2015 55
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2015 56
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Scynexis, Inc., H1 2015 57
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H1 2015 58
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H1 2015 59
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by SIFI S.p.A, H1 2015 60
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Winston Pharmaceuticals, Inc., H1 2015 61
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H1 2015 62
Assessment by Monotherapy Products, H1 2015 63
Number of Products by Stage and Target, H1 2015 65
Number of Products by Stage and Mechanism of Action, H1 2015 68
Number of Products by Stage and Route of Administration, H1 2015 70
Number of Products by Stage and Molecule Type, H1 2015 72
Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Recent Pipeline Updates, H1 2015 141
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2015 163
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H1 2015 164
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H1 2015 165
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H1 2015 166
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H1 2015 167